Evaluation of the Side Effect Profile of Intracavitary Bacillus Calmette-Guerin Treatment in Non-muscle-invasive Bladder Cancer

Abstract

Objective: To reveal the association of side effect profiles seen in patients receiving intravesical bacillus Calmette-Guerin (BCG) immunotherapy for non-muscle-invasive bladder cancer (NMIBC) treatment with patient age and possible changes over time due to the use of different BCG strains.